In vivo, using the subcutaneous MB49 bladder cancer model, HSV5-15 virus expressing both the cytokine and TLR agonist ...

The phase 2 BRACELET-1 trial demonstrated that the combination of pelareorep and paclitaxel significantly improved outcomes ...

CF33-hNIS has gained FDA orphan drug designation for the treatment of cholangiocarcinoma and is currently being evaluated in ...

Preliminary data presented at ESMO 2024 demonstrate that BT-001 induces tumor regression in patients who failed previous anti-PD(L)-1 treatmentIn a patient with a heavily pretreated leiomyosarcoma, BT ...

ImmVira announced the latest clinical results for its lead oncolytic virus product, MVR-T3011, via intravesical administration in patients with high-risk BCG-failure non-muscle invasive bladder cancer ...

The global cancer gene therapy market is set for significant expansion, with projections indicating a robust compound annual ...

HELSINKI, Sept. 09, 2024 (GLOBE NEWSWIRE) -- TILT Biotherapeutics (TILT), a clinical-stage biotechnology company developing cancer immunotherapies, announces that it will present data at the European ...

Oncolytic virus BT-001 was shown to replicate and express ... that discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapy, with currently five drug candidates ...

BT-001 monotherapy showed stable disease and shrinkage of injected lesions in patients with advanced solid tumors. BT-001 in combination with ...

BT-001 monotherapy showed stable disease and injected lesions shrinkage in advanced solid tumor patients. Promising efficacy ...

Laser therapy is a tool that physicians and surgeons can use to treat a variety of conditions. "Laser" stands for "light amplification by stimulated emission of radiation." It uses intense beams of ...